The Kynurenine Pathway in Traumatic Brain Injury: Implications for Psychiatric Outcomes.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and observational literature without systematic methodology
PubMed 34266671 · doi:10.1016/j.biopsych.2021.05.021
What was done
The authors conducted a narrative literature review examining the role of the kynurenine pathway of tryptophan metabolism in traumatic brain injury (TBI) and evaluated its potential mechanistic link to psychiatric outcomes such as depression and anxiety.
What was found
The abstract provides no numerical data, statistics, or effect sizes. It qualitatively reports that TBI across all severities is associated with increased production of neurotoxic kynurenines such as quinolinic acid. Elevated quinolinic acid concentrations in cerebrospinal fluid and blood are reported to associate with mortality, magnetic resonance imaging abnormalities, elevated depressive and anxiety symptoms, and prolonged recovery.
Why it matters
The paper synthesizes evidence for a mechanistic framework linking post-TBI neuroinflammation to psychiatric sequelae via neurotoxic tryptophan metabolites. If validated, these metabolites could serve as prognostic biomarkers or targets for pharmacological interventions.
Limits
This is a narrative review rather than a systematic review or meta-analysis, presenting synthesized conclusions without quantitative metrics, sample sizes, or study counts in the abstract. The proposed causal role of kynurenine pathway alterations in producing post-TBI psychiatric disorders remains a hypothesis requiring prospective human validation.
Cited by
- supports Kynurenic acid acts as an NMDA receptor antagonist, whereas quinolinic acid acts as an NMDA receptor agonist with neurotoxic properties.